胰高血糖素样肽-1 受体激动剂对 2 型糖尿病患者肾功能及安全性的影响。
Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.
机构信息
Division of Endocrinology, Department of Internal Medicine, Hallym University College of Medicine, Kangdong Sacred Heart Hospital, Seoul, Korea.
出版信息
J Diabetes Investig. 2021 Jun;12(6):914-916. doi: 10.1111/jdi.13552. Epub 2021 May 7.
Abstract
Glucagon-like peptide-1 receptor agonists have been recommended in diabetic kidney disease patients.
摘要
胰高血糖素样肽-1 受体激动剂已被推荐用于糖尿病肾病患者。
相似文献
1
Effects of glucagon-like peptide-1 receptor agonists on kidney function and safety in type 2 diabetes patients.
J Diabetes Investig. 2021 Jun;12(6):914-916. doi: 10.1111/jdi.13552. Epub 2021 May 7.
2
Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Nat Rev Nephrol. 2017 Dec;13(12):728-730. doi: 10.1038/nrneph.2017.140. Epub 2017 Oct 9.
3
New Glucose-Lowering Agents for Diabetic Kidney Disease.
Adv Chronic Kidney Dis. 2018 Mar;25(2):149-157. doi: 10.1053/j.ackd.2018.01.002.
4
GLP-1 Receptor Agonists in Diabetic Kidney Disease.
Clin J Am Soc Nephrol. 2021 Oct;16(10):1578-1580. doi: 10.2215/CJN.18771220. Epub 2021 Apr 13.
5
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868.
6
Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk.
Lancet Diabetes Endocrinol. 2020 Feb;8(2):97-99. doi: 10.1016/S2213-8587(19)30414-0. Epub 2019 Dec 13.
7
Impact of CVOTs in primary and secondary prevention of kidney disease.
Diabetes Res Clin Pract. 2019 Nov;157:107907. doi: 10.1016/j.diabres.2019.107907. Epub 2019 Oct 30.
8
Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
Diabetes Obes Metab. 2019 Aug;21(8):1790-1800. doi: 10.1111/dom.13743. Epub 2019 May 2.
9
Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes.
Int J Mol Sci. 2019 Nov 20;20(23):5831. doi: 10.3390/ijms20235831.
10
Impact of glucagon like peptide-1 receptor agonist and sodium glucose cotransporter 2 inhibitors on type 2 diabetes patients with renal impairment.
Diab Vasc Dis Res. 2020 Nov-Dec;17(6):1479164120971220. doi: 10.1177/1479164120971220.
引用本文的文献
1
Incretin hormones: Revolutionizing the treatment landscape for kidney and liver diseases in type 2 diabetes and obesity.
J Diabetes Investig. 2025 Feb;16(2):183-186. doi: 10.1111/jdi.14336. Epub 2024 Oct 26.
2
Semaglutide in renal ischemia-reperfusion injury in mice.
J Med Life. 2023 Feb;16(2):317-324. doi: 10.25122/jml-2022-0291.
3
Updates of incretin-related drugs for the treatment of type 2 diabetes.
J Diabetes Investig. 2023 Feb;14(2):189-192. doi: 10.1111/jdi.13945. Epub 2022 Nov 14.
本文引用的文献
1
Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
Lancet Diabetes Endocrinol. 2020 Nov;8(11):880-893. doi: 10.1016/S2213-8587(20)30313-2. Epub 2020 Sep 21.
2
The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes.
Diabetes Ther. 2020 Apr;11(4):835-844. doi: 10.1007/s13300-020-00798-x. Epub 2020 Mar 17.
3
GLP-1 Receptor Agonists and Kidney Protection.
Medicina (Kaunas). 2019 May 31;55(6):233. doi: 10.3390/medicina55060233.
4
Glucagon-Like Peptide 1 and Its Cleavage Products Are Renoprotective in Murine Diabetic Nephropathy.
Diabetes. 2018 Nov;67(11):2410-2419. doi: 10.2337/db17-1212. Epub 2018 Aug 13.
5
The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
Diabetes Metab. 2017 Apr;43 Suppl 1:2S20-2S27. doi: 10.1016/S1262-3636(17)30069-1.
6
Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
Diabetes Metab. 2015 Jun;41(3):183-94. doi: 10.1016/j.diabet.2015.02.003. Epub 2015 Mar 18.
7
The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential.
Kidney Int. 2014 Mar;85(3):579-89. doi: 10.1038/ki.2013.427. Epub 2013 Oct 23.
Zotero 插件